RxDoctor Payments Data

Jose Mayans, MD

Ophthalmology · Odessa, TXNPI 1124177654

Payments from drug & device makers

$462in general payments, 2019–2025

Across 13 payments — averaging $35.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$111
  • Aerie Pharmaceuticals, Inc.$80
  • AbbVie$73
  • Bausch & Lomb Americas Inc.$62
  • Genentech, Inc.$47
  • Amgen$37
  • plus $52 from 3 others

What the payments were for

  • Food & beverage$41590%
  • Education$4710%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$462 in reported general payments places this provider in the 20th percentile of 1,355 ophthalmology providers in Texas.

See all ophthalmology providers in Texas

Medicare billing

Part B allowed, 2024
$228,331
Medicare patients
426
Services billed
2,612

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost102$36,530
RestasisCyclosporine33$33,717
XiidraLifitegrast14$14,948
SimbrinzaBrinzolamide/Brimonidine Tart48$10,409
RocklatanNetarsudil Mesylat/Latanoprost27$10,292
Prednisolone Acetate213$9,112
VyzultaLatanoprostene Bunod30$8,345
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol44$7,201
RhopressaNetarsudil Mesylate19$6,532
Latanoprost936$6,386
Brimonidine Tartrate123$6,242
Lotemax SmLoteprednol Etabonate24$5,981
Travoprost51$3,769
Alphagan PBrimonidine Tartrate15$3,462
Dorzolamide-TimololDorzolamide/Timolol/Pf21$3,130

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis, Alphagan P, Combigan$73$76,746161 claims
Bausch & Lomb Americas Inc.Xiidra, Vyzulta$62$23,29344 claims
Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa$80$16,82446 claims
AlconSimbrinza$111$10,40948 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 1,355 ophthalmology providers in Texas.

Other ophthalmology in Odessa

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →